| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/01/1999 | WO1999032118A1 Molecular dispersion composition with enhanced bioavailability |
| 07/01/1999 | WO1999032117A1 Novel substituted pyridine compounds useful as modulators of acetylcholine receptors |
| 07/01/1999 | WO1999032111A1 INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS |
| 07/01/1999 | WO1999032110A1 INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
| 07/01/1999 | WO1999032106A1 Inhibition of raf kinase using substituted heterocyclic ureas |
| 07/01/1999 | WO1999032099A2 Use of fucane for regulating the reconstruction of connective tissues |
| 07/01/1999 | WO1999032098A2 Combination of a ramba and a tocopherol |
| 07/01/1999 | WO1999032085A2 Novel pharmaceutical compositions of uridine triphosphate |
| 07/01/1999 | WO1999032082A2 Pharmaceutical compositions |
| 07/01/1999 | WO1999032077A1 Use of amino phenol amide derivatives as depigmentation agents |
| 07/01/1999 | WO1999025832A8 Toso |
| 07/01/1999 | WO1999020121A3 Methods for obtaining protein mixtures and control factors from wound granulation, epithelialization or determined blastocyst tissue |
| 07/01/1999 | WO1999018801A9 Methods and compositions for the treatment of autoimmune disease using heat shock proteins |
| 07/01/1999 | WO1999015186A8 Cationic polymers as toxin-binding agents |
| 07/01/1999 | WO1999010014A3 Receptor-mediated gene delivery using bacteriophage vectors |
| 07/01/1999 | WO1999003817B1 Aliphatic propargylamines as cellular rescue agents |
| 07/01/1999 | DE19756848A1 Extrakte aus Blättern von Ginkgo biloba mit vermindertem Gehalt an 4'-O-Methylpyridoxin und Biflavonen Extracts from leaves of Ginkgo biloba with a reduced content of 4'-O-methyl and biflavones |
| 07/01/1999 | DE19756236A1 Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide New piperazinyl substituted pyridylalkane, alkene and -alkincarbonsäureamide |
| 07/01/1999 | DE19756212A1 Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide Novel substituted with a cyclic imide pyridylalkane, alkene and -alkincarbonsäureamide |
| 07/01/1999 | CA2316971A1 Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
| 07/01/1999 | CA2316018A1 Novel pharmaceutical compositions of uridine triphosphate |
| 07/01/1999 | CA2315941A1 Novel substituted pyridine compounds useful as modulators of acetylcholine receptors |
| 07/01/1999 | CA2315720A1 Inhibition of p38 kinase activity using substituted heterocyclic ureas |
| 07/01/1999 | CA2315245A1 Secreted proteins and polynucleotides encoding them |
| 07/01/1999 | CA2315070A1 Ortho-anthranilamide derivatives as anti-coagulants |
| 07/01/1999 | CA2315037A1 Methods and compositions for inhibiting tumor cell growth |
| 07/01/1999 | CA2314980A1 Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses |
| 07/01/1999 | CA2314925A1 Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists |
| 07/01/1999 | CA2314614A1 A dna molecule encoding a mutant prepro-neuropeptide y, a mutant signal peptide, and uses thereof |
| 07/01/1999 | CA2313163A1 Pharmaceutical compositions |
| 07/01/1999 | CA2312712A1 Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists |
| 07/01/1999 | CA2312070A1 1,4-diazacycloheptane derivatives |
| 07/01/1999 | CA2307221A1 Polycyclic .alpha.-amino-e-caprolactams and related compounds |
| 07/01/1999 | CA2305436A1 Ace inhibitor-mmp inhibitor combinations |
| 07/01/1999 | CA2303483A1 Sag: sensitive to apoptosis gene |
| 07/01/1999 | CA2300197A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
| 07/01/1999 | CA2280950A1 Use of amino phenol amide derivatives as depigmentation agents |
| 06/30/1999 | EP0926145A1 Napthalene compounds, method for their preparation and pharmaceutical compositions containing them |
| 06/30/1999 | EP0926137A1 Picolin acid derivatives useful in the treatment of IL-1 and TNF mediated diseases |
| 06/30/1999 | EP0925360A1 Angiogenic factor and use thereof in treating cardiovascular disease |
| 06/30/1999 | EP0925307A1 Enzyme and dna sequence encoding same |
| 06/30/1999 | EP0925303A1 Phosphinic acid amides as matrix metalloprotease inhibitors |
| 06/30/1999 | EP0925299A1 Pyrazolopyridine compound and pharmaceutical use thereof |
| 06/30/1999 | EP0925298A1 Substituted 6,6-hetero-bicyclic derivatives |
| 06/30/1999 | EP0925297A1 Endothelin receptor antagonists |
| 06/30/1999 | EP0925294A1 Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels |
| 06/30/1999 | EP0925291A1 Spirocyclic dopamine receptor subtype ligands |
| 06/30/1999 | EP0925289A1 Matrix metalloproteinase inhibitors |
| 06/30/1999 | EP0925287A1 Heterocyclic metalloprotease inhibitors |
| 06/30/1999 | EP0925286A1 Substituted pyrimidine derivatives and their pharmaceutical use |
| 06/30/1999 | EP0925071A1 Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions |
| 06/30/1999 | EP0925070A1 Antifungal combination therapy |
| 06/30/1999 | EP0925067A1 Composition and method for repairing neurological tissue |
| 06/30/1999 | EP0924985A1 Method for inhibiting the expression of fas |
| 06/30/1999 | CN1221449A Modulators of TNF receptor associated factor (TRAF), their preparation and use |
| 06/30/1999 | CN1221414A Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 06/30/1999 | CN1221347A Medicament for optimising mucosal viscosity and stimulating intestinal function |
| 06/30/1999 | CN1221344A Extractable compounds and method for making and using the same |
| 06/30/1999 | CN1221339A Use of inhibitors of cellular Na+/H+ exchanger (NHE) for preparing medicament for normalizing serum lipids |
| 06/30/1999 | CN1043884C New substituted azacylobutanone, preparation method and medicinal use thereof |
| 06/30/1999 | CA2256002A1 7-bromo- and 7,7-dibromo-cepham and cephem derivatives |
| 06/29/1999 | US5917082 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
| 06/29/1999 | US5917048 Substituted aryl or heteroarylamides having retinoid-like biological activity |
| 06/29/1999 | US5917014 Methods of treating inflammation and compositions therefor |
| 06/29/1999 | US5916916 Useful as selective estrogen receptor modulators. |
| 06/29/1999 | US5916912 Orally administering to the host an effective dosage of a carnitine, such as acetyl-l-carnitine, and a mitochondrially active antioxidant, such as lipoic acid; restores mitochondiral functions; mitigation of indicia of aging |
| 06/29/1999 | US5916910 Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
| 06/29/1999 | US5916908 Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
| 06/29/1999 | US5916906 Compositions comprising nicotinylalanine and an inhibitor of glycine conjugation or vitamin B6 |
| 06/29/1999 | US5916897 Process for the preparation of 9-amino camptothecin |
| 06/29/1999 | US5916894 Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
| 06/29/1999 | US5916887 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators |
| 06/29/1999 | US5916870 Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
| 06/29/1999 | US5916792 Jak3 plays a role in the growth factor modulated differentiation/proliferation of the stem/progenitor cells. |
| 06/29/1999 | US5916769 Polynucleotides encoding extra cellular/epidermal growth factor HCABA58X polypepides |
| 06/29/1999 | US5916595 HMG co-reductase inhibitor |
| 06/29/1999 | US5916590 Soft gelatin pharmaceutical dosage form |
| 06/29/1999 | US5916582 Aqueous formulations of peptides |
| 06/29/1999 | US5916576 Orange extract obtained from orange peel, orange flowers or orange leaves and contains less than 1% ascorbic acid; anti-radical activity towards superoxide radical; antiaging agent; cosmetics |
| 06/29/1999 | US5916560 Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith |
| 06/29/1999 | CA2134211C Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient |
| 06/29/1999 | CA2125974C Senescent cell derived inhibitors of dna synthesis |
| 06/29/1999 | CA1340614C Cyclopentano-vitamin d analogs |
| 06/24/1999 | WO1999031268A1 Agonists of metabotropic glutamate receptors and uses thereof |
| 06/24/1999 | WO1999031232A1 Human brain derived kcnq2 potassium channel |
| 06/24/1999 | WO1999031140A1 TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 06/24/1999 | WO1999031136A2 Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells |
| 06/24/1999 | WO1999031135A1 Proteins for cancer cell specific induction of apoptosis and method for isolation thereof |
| 06/24/1999 | WO1999031134A1 Glucose regulated gene |
| 06/24/1999 | WO1999031128A2 Human tumor necrosis factor-r2-like proteins |
| 06/24/1999 | WO1999031112A1 Vitamin d derivatives with phosphorous atoms in the side chains |
| 06/24/1999 | WO1999031105A1 3-substituted adenines via2-thioxanthines |
| 06/24/1999 | WO1999031104A1 Preparation of 3-substituted adenines and imidazo pyridines |
| 06/24/1999 | WO1999031103A1 Preparation of 3-substituted adenines |
| 06/24/1999 | WO1999031102A1 Purine derivatives having phosphodiesterase iv inhibition activity |
| 06/24/1999 | WO1999031099A1 Integrin receptor antagonists |
| 06/24/1999 | WO1999031092A1 Benzamine derivatives |
| 06/24/1999 | WO1999031088A1 Triazine angiogenesis inhibitors |
| 06/24/1999 | WO1999031087A1 Cyclic imide-substituted pyridylalkane, alkene and alkine carboxamides useful as cytostatic and immunosuppressive agents |
| 06/24/1999 | WO1999031086A1 Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists |